Skip to Content

Brentuximab Dosage

Applies to the following strength(s): 50 mg

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Lymphoma

1.8 mg/kg intravenously over 30 minutes every 3 weeks.

Continue treatment until disease progression or unacceptable toxicity.

Renal Dose Adjustments

Data not available.

Liver Dose Adjustments

Data not available.

Dose Adjustments

No dosage adjustment is recommended based on gender, race, or age.

Peripheral neuropathy should be managed using a combination of dose delay and dose reduction to 1.2 mg/kg. For new or worsening Grade 2 or 3 neuropathy, dosing should be held until neuropathy improves to Grade 1 or baseline and then restarted at 1.2 mg/kg. For Grade 4 peripheral neuropathy, brentuximab vedotin should be discontinued.

Neutropenia should be managed by dose delays and reductions. The dose of brentuximab vedotin should be held for Grade 3 or 4 neutropenia until resolution to baseline or Grade 2 or lower. Growth factor support should be considered for subsequent cycles in patients who experience Grade 3 or 4 neutropenia. In patients with recurrent Grade 4 neutropenia despite the use of growth factors, discontinuation or dose reduction to 1.2 mg/kg may be considered.


PML should be a consideration for any patient presenting with new onset signs and symptoms of central nervous system abnormalities. Hold brentuximab vedotin dosing for any suspected case of PML and discontinue brentuximab vedotin if a diagnosis of PML is confirmed.

Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain or weakness. Patients experiencing new or worsening peripheral neuropathy may require a delay, change in dose, or discontinuation of brentuximab vedotin.

Complete blood counts should be monitored prior to each dose of brentuximab vedotin and more frequent monitoring should be considered for patients with Grade 3 or 4 neutropenia. Prolonged (one week or longer) severe neutropenia can occur with brentuximab vedotin. If Grade 3 or 4 neutropenia develops, manage by dose delays, reductions, or discontinuations

Tumor lysis syndrome may occur. Patients with rapidly proliferating tumor and high tumor burden may be at increased risk of tumor lysis syndrome. Monitor closely and take appropriate measures.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available.

Other Comments

The manufacturer's product information should be consulted for complete reconstitution and dilution recommendations.